Terms ending in 2040
Every in-force patent on Biodesix, Inc.'s record whose computed term ends in 2040, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,710,539 | Predictive Test for Melanoma Patient Benefit from Interleukin-2 (IL2) Therapy In force · High confidence | Biodesix, Inc. | In force | High confidence | |
| US 11,621,057 | Classifier Generation Methods and Predictive Test for Ovarian Cancer Patient Prognosis Under Platinum Chemotherapy In force · High confidence | Biodesix, Inc. | In force | High confidence | |
| US 12,802,815 | Method for Identification of Cancer Patients with Durable Benefit from Immunotherapy in Overall Poor Prognosis Subgroups In force · High confidence | Biodesix, Inc. | In force | High confidence |
3 of 3 patents shown. Soonest term end first, then patent number.
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.